<?xml version="1.0" encoding="UTF-8"?>
<ref id="ajh25238-bib-0029">
 <label>29</label>
 <mixed-citation publication-type="journal" id="ajh25238-cit-0029">
  <string-name>
   <surname>Savona</surname>
   <given-names>MR</given-names>
  </string-name>, 
  <string-name>
   <surname>Pollyea</surname>
   <given-names>DA</given-names>
  </string-name>, 
  <string-name>
   <surname>Stock</surname>
   <given-names>W</given-names>
  </string-name>, et al. 
  <article-title>Phase IB study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high‐risk MDS</article-title>. 
  <source xml:lang="en">Clin Cancer Res.</source>
  <year>2018</year>;
  <volume>24</volume>:
  <fpage>2294</fpage>‐
  <lpage>2303</lpage>.
  <pub-id pub-id-type="pmid">29463550</pub-id>
 </mixed-citation>
</ref>
